12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dificid: Phase IIIb started

Optimer began the double-blind, placebo-controlled, U.S. Phase IIIb DEFLECT-1 trial to evaluate 200 mg oral Dificid once daily in about 340 patients undergoing hematopoietic stem cell transplant (HSCT). Dificid is approved to treat CDAD in the U.S. and the EU, where it is known as Dificlir....

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >